Evaluating new imaging techniques to predict treatment success in glioblastoma
Assessment Of A Novel Metabolic Imaging Modalities As A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)
PHASE2 · Stanford University · NCT06855628
This study is testing a new imaging method to see if it can help predict how well a treatment for glioblastoma will work when combined with standard care.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University (other) |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT06855628 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the prognostic ability of a novel metabolic imaging modality in predicting the therapeutic efficacy of BPM31510, a lipid nano dispersion of CoQ10, when added to standard glioblastoma treatment. Participants will undergo imaging with [6,6-²H₂]-Glucose to evaluate how well this method can forecast treatment outcomes. The study is part of a Phase II trial that includes patients consenting to the parent study. The goal is to enhance treatment strategies for glioblastoma by identifying effective predictors of response.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with glioblastoma who are willing to participate in the Phase II BPM31510 study.
Not a fit: Patients who refuse IV administration or have allergies to MRI contrasts may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for glioblastoma patients by identifying those who are more likely to benefit from specific therapies.
How similar studies have performed: Other studies have shown promise in using metabolic imaging to predict treatment outcomes, suggesting that this approach may be viable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any participant that consents to entry into the Phase II BPM31510 parent study (BPM31510IV-11) * Women of childbearing potential must have a negative pregnancy test * Ability to understand and the willingness to provide written informed consent. Exclusion Criteria: * Refuse to have an IV * Allergy to MRI contrasts * Diabetic patients who are taking insulin
Where this trial is running
Palo Alto, California
- Stanford University — Palo Alto, California, United States (RECRUITING)
Study contacts
- Principal investigator: Lawarence Recht — Stanford University
- Study coordinator: Lewis Naya
- Email: lnaya@stanford.edu
- Phone: (650) 725-0379
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.